241 related articles for article (PubMed ID: 16637061)
1. Prostate cancer chemoprevention by silibinin: bench to bedside.
Singh RP; Agarwal R
Mol Carcinog; 2006 Jun; 45(6):436-42. PubMed ID: 16637061
[TBL] [Abstract][Full Text] [Related]
2. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Blouin MJ; Singh RP; Majeed N; Deep G; Varghese L; Glodé LM; Greenberg NM; Hwang D; Cohen P; Pollak MN; Agarwal R
Cancer Res; 2007 Nov; 67(22):11083-91. PubMed ID: 18006855
[TBL] [Abstract][Full Text] [Related]
3. A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer.
Singh RP; Agarwal R
Mutat Res; 2004 Nov; 555(1-2):21-32. PubMed ID: 15476849
[TBL] [Abstract][Full Text] [Related]
4. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action.
Harper CE; Patel BB; Wang J; Eltoum IA; Lamartiniere CA
Prostate; 2007 Oct; 67(14):1576-89. PubMed ID: 17705241
[TBL] [Abstract][Full Text] [Related]
5. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft.
Singh RP; Deep G; Blouin MJ; Pollak MN; Agarwal R
Carcinogenesis; 2007 Dec; 28(12):2567-74. PubMed ID: 17916909
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of action of novel agents for prostate cancer chemoprevention.
Singh RP; Agarwal R
Endocr Relat Cancer; 2006 Sep; 13(3):751-78. PubMed ID: 16954429
[TBL] [Abstract][Full Text] [Related]
7. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels.
Singh RP; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
Cancer Res; 2002 Jun; 62(11):3063-9. PubMed ID: 12036915
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer and inositol hexaphosphate: efficacy and mechanisms.
Singh RP; Agarwal R
Anticancer Res; 2005; 25(4):2891-903. PubMed ID: 16080543
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells.
Tyagi A; Bhatia N; Condon MS; Bosland MC; Agarwal C; Agarwal R
Prostate; 2002 Nov; 53(3):211-7. PubMed ID: 12386921
[TBL] [Abstract][Full Text] [Related]
10. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells.
Fang J; Zhou Q; Shi XL; Jiang BH
Carcinogenesis; 2007 Mar; 28(3):713-23. PubMed ID: 17065200
[TBL] [Abstract][Full Text] [Related]
11. Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells.
Deep G; Oberlies NH; Kroll DJ; Agarwal R
Carcinogenesis; 2007 Jul; 28(7):1533-42. PubMed ID: 17389612
[TBL] [Abstract][Full Text] [Related]
12. Chemopreventive efficacy of silymarin in skin and prostate cancer.
Deep G; Agarwal R
Integr Cancer Ther; 2007 Jun; 6(2):130-45. PubMed ID: 17548792
[TBL] [Abstract][Full Text] [Related]
13. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
McCarty MF
Integr Cancer Ther; 2004 Dec; 3(4):349-80. PubMed ID: 15523106
[TBL] [Abstract][Full Text] [Related]
14. Targeting silibinin in the antiproliferative pathway.
Li L; Zeng J; Gao Y; He D
Expert Opin Investig Drugs; 2010 Feb; 19(2):243-55. PubMed ID: 20047507
[TBL] [Abstract][Full Text] [Related]
15. Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors.
Wu K; Zeng J; Li L; Fan J; Zhang D; Xue Y; Zhu G; Yang L; Wang X; He D
Oncol Rep; 2010 Jun; 23(6):1545-52. PubMed ID: 20428808
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
17. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells.
Zi X; Zhang J; Agarwal R; Pollak M
Cancer Res; 2000 Oct; 60(20):5617-20. PubMed ID: 11059749
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
19. CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells.
Deeb D; Gao X; Dulchavsky SA; Gautam SC
J Exp Ther Oncol; 2008; 7(1):31-9. PubMed ID: 18472640
[TBL] [Abstract][Full Text] [Related]
20. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents.
Agarwal R
Biochem Pharmacol; 2000 Oct; 60(8):1051-9. PubMed ID: 11007941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
